MLYS · Mineralys Therapeutics, Inc.
$26.72
-0.18 (-0.67%)
At close · Jul 29
Market Cap
$2.22B
Shares
82.50M
Mineralys Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Mineralys Therapeutics, Inc. (MLYS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Mineralys Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
Unmet need in resistant hypertension
Partnering and business development
Clinical data package and differentiation
Diluted EPS
$-0.47
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Mineralys Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
FDA NDA acceptance and PDUFA date
EXPLORER-OSA trial results (mixed)
Life-cycle and indication expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Mineralys Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
Lorundrostat clinical efficacy in hypertension
Label-expansion indications (CKD, OSA, heart failure)
NDA submission progress
Diluted EPS
$-0.52
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Mineralys Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
Lorundrostat pivotal data and differentiation
Lifecycle extension in CKD and OSA
Pre-commercial readiness and partnering
Diluted EPS
$-0.66
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Mineralys Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
Pivotal Phase 3 Trial Results (Launch-HTN and Advance-HTN)
Commercial Opportunity and Physician Interest
Explore-CKD Trial (Chronic Kidney Disease)
Diluted EPS
$-0.79
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Mineralys Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Lorundrostat Drug Profile
Pivotal Trial Readouts (Advance-HTN and Launch-HTN)
Explore-CKD Phase II Trial
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mineralys Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Pivotal Advance-HTN trial
Pivotal Launch-HTN trial
Explore-CKD Phase II trial
Diluted EPS
$-1.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Mineralys Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
Lorundrostat Pivotal Program / Hypertension
FDA Alignment & Trial Design
Competitive Landscape (MRAs vs ASI)
Diluted EPS
$-0.83
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Mineralys Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Pivotal Hypertension Trials
Targeted/Precision Medicine Strategy
CKD Proof-of-Concept Trial
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Mineralys Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
Pivotal hypertension program (Advance-HTN / Launch-HTN)
Explore-CKD Phase 2 trial
Obesity / GLP-1 interplay and differentiation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Mineralys Therapeutics, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.57
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Mineralys Therapeutics, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.31
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Mineralys Therapeutics, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.51
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Mineralys Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–16 of 16 earnings calls
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
22 filings
22 filers
Visit website
Investor relations